Sangamo BioSciences traded at $0.14 this Friday May 15th, decreasing $0.001 or 0.37 percent since the previous trading session. Looking back, over the last four weeks, Sangamo BioSciences lost 50.00 percent. Over the last 12 months, its price fell by 71.28 percent. Looking ahead, we forecast Sangamo BioSciences to be priced at 0.13 by the end of this quarter and at 0.12 in one year, according to Trading Economics global macro models projections and analysts expectations.
Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company. The Company is focused on translating science into medicines that transform the lives of patients with serious diseases. Its product candidates include Giroctocogene fitelparvovec (SB-525), ST-920, SAR445136, ST-400 and TX200. Its SB-525, is a lead product candidate, a gene therapy for the treatment of hemophilia A. Its ST-920, is a gene therapy product candidate for the treatment of fabry disease. SAR445136, is its cell therapy product candidate for the treatment of sickle cell disease (SCD). Its ST-400 is a cell therapy product candidate for the treatment of transfusion dependent beta thalassemia. Its TX200, is a chimeric antigen receptor (CAR), engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the treatment of HLA-A2 mismatched kidney transplant rejection.